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(EPC Technical Papers Series, 2012). They 
included RCTs of at least 4 weeks duration, 
using EPA + DHA supplementation less 
than 6 g/day. The summary relative risks 
for all-cause mortality (17 trials, 51,264 
patients) and cardiovascular mortality (14 
trials, 48,500 patients) were 0.95 (95% CI: 
0.89–1.01) and 0.89 (95% CI: 0.83–0.96), 
respectively. Whether you believe omega-3 
fatty acid supplementation reduces car-
diovascular mortality or not would seem 
to depend on which meta-analysis you 
prefer. However, since the studies included 
in both of these reviews are so diverse, a 
meta-analysis is not the most appropriate 
method to answer our question. A look 
at the differences among the large RCTs 
which were specifically designed to assess 
cardiovascular morbidity and mortality 
will shed more light, and at least clarify 
what are the unresolved issues.
Only eight RCTs have been of sufficient 
size (n = 2000–18,000) to provide adequate 
power for detecting statistically meaning-
ful results (Kromhout et al., 1985, 2010, 
2011; Burr et al., 1989; GISSI-Prevenzione 
Investigators, 1999; Yokoyama et al., 2007a,b; 
The GISSI-HF investigators, 2008; Galan 
et al., 2010; Rauch et al., 2010; The ORIGIN 
Trial Investigators, 2012). Trial designs, 
n−3 fatty acid doses, and study popula-
tion characteristics were quite different. In 
summary, GISSI-Prevenzione Investigators 
(1999) and DART (1989) showed a large 
CV mortality benefit; JELIS (2007) showed 
a reduction in non-fatal CV events, but no 
effect on mortality; The GISSI-HF inves-
tigators (2008) showed a small mortality 
benefit in CHF patients; The ORIGIN Trial 
Investigators (2012), Omega (2010), Alpha-
Omega (2010), and SU.FOL.OM3 (2010) 
showed no CV benefits (fatal or non-fatal) 
in their overall trial results. It should also 
the vitamin supplement trials, for exam-
ple, results derived from the whole study 
population have sometimes been opposite 
from the results from the “deficient” sub-
population (Morris and Tangney, 2011; 
Rimm and Stampfer, 2011).
There have been about 20 published tri-
als in which patients were randomized to 
a daily dose of n−3 fatty acid vs. placebo 
and who were then followed for varying 
intervals in order to assess some type of 
cardiovascular disease outcome. Most of 
these were performed in patients with a 
history of CHD.
Two recently published meta-analyses 
reached divergent conclusions. Kwak et al. 
(2012) performed a meta-analysis of 14 
trials, and concluded that there was insuf-
ficient evidence of a preventive effect of 
omega-3 fatty acid supplements against 
overall cardiovascular events among 
patients with a history of cardiovascu-
lar disease. The authors note that there 
was a small reduction in cardiovascular 
death (RR 0.91; 95% CI: 0.84–0.99), which 
disappeared when one study with major 
methodological problems was excluded. 
Quality of a meta-analysis in predicated 
upon the quality of the individual stud-
ies and on the amount of heterogeneity 
among the studies. In this case, all but 
four of these trials had less than 600 
participants, half lasted no more than a 
year, several were designed with angio-
graphic endpoints, and three were per-
formed in patients with implantable 
cardioverter-defibrillators (ICDs), using 
ICD discharges as the primary endpoint. 
General conclusions from such a meta-
analysis are therefore highly speculative. 
The Agency for Healthcare Research 
and Quality also performed a systematic 
review with random effects meta-analysis 
As often the case within scientific research, 
the answer is not as straightforward as the 
question. In contradistinction to earlier 
data, recently published studies have been 
negative, and thus raised the question of 
whether supplementation with omega-3 
fatty acids for prevention of cardiovascu-
lar disease is now passé. Some background 
knowledge is necessary to appreciate this 
perplexing and controversial topic.
Observational studies performed 
within the general population over the past 
40 years have almost uniformly noted an 
inverse relationship between fatty fish or 
n−3 fatty acid consumption and morbid-
ity or mortality from coronary heart dis-
ease (CHD; Kromhout et al., 1985, 2010, 
2011; Dolecek, 1992; Rodriguez et al., 
1996; Daviglus et al., 1997; Albert et al., 
1998, 2002; Oomen et al., 2000; Iso et al., 
2001; Yuan et al., 2001; Hu et al., 2002, 
2003; Lemaitre et al., 2003; Mozaffarian 
et al., 2003; He et al., 2004; Panagiotakos 
et al., 2005; Mozaffarian and Rimm, 2006; 
Bjerregaard et al., 2010). Likewise, among 
studies which measured blood or tissue 
levels of n−3 fatty acids the majority have 
shown the same inverse correlation with 
cardiovascular disease events (Siscovick 
et al., 1995; Albert et al., 1998, 2002; Harris 
et al., 2007; Block et al., 2008; Park et al., 
2009; Pottala et al., 2010). However, obser-
vational data can never prove cause-and-
effect. Randomized clinical trials (RCT) 
have been designed specifically to pro-
vide a more controlled evaluation of the 
effects of omega-3 fatty acids treatment on 
adverse cardiovascular events. However, 
RCTs have their own limitations, espe-
cially when the interventional agent being 
tested is one that is available in food and 
consumed in varying amounts by the pop-
ulation participating in the trial. Among 
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possibly be a marker for who deri-
ves some CVD benefit from omega-3 
supplementation.
4. Omega-3 dose – All of the large trials to 
date have used doses of 1 g or less per 
day, except JELIS, which although an 
open-label study, showed a 19% reduc-
tion in non-fatal CV events. Therefore, 
what is the most effective dose remains 
an unanswered question that will not 
be resolved by any of the studies cur-
rently in progress (ASCEND, Rishio e 
Prevenzione, and VITAL, all of which 
use <1 g/day).
At this time, it is not possible to defini-
tively answer our original question. The 
factors enumerated above may or may 
not explain the discrepancies observed in 
the omega-3 trial outcomes, but each one 
formulates a reasonable hypothesis which 
needs to be addressed in future research. 
Otherwise, those who believe the latest 
research has now established that there is 
no role for omega-3 fatty acids in preven-
tion of CVD may be throwing the proverbial 
baby out with the bathwater, and thereby 
deprive certain patients a potentially valu-
able therapy.
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